Geode Capital Management’s NeuroSense Therapeutics NRSN Stock Holding History

Geode Capital Management’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12K	Hold	15,870	–	–	﹤0.01%	4483
2025 Q4	$12.2K	Hold	15,870	–	–	﹤0.01%	4422
2025 Q3	$19.8K	Hold	15,870	–	–	﹤0.01%	4418
2025 Q2	$30K	Hold	15,870	–	–	﹤0.01%	4306
2025 Q1	$14.6K	Hold	15,870	–	–	﹤0.01%	4404
2024 Q4	$19K	Buy	15,870 +3,907	+33%	+$4.49K	﹤0.01%	4391
2024 Q3	$15.2K	Hold	11,963	–	–	﹤0.01%	4426
2024 Q2	$13.4K	Hold	11,963	–	–	﹤0.01%	4516
2024 Q1	$21.8K	Hold	11,963	–	–	﹤0.01%	4473
2023 Q4	$9.39K	Buy	+11,963	New	+$7.95K	﹤0.01%	4596

Other funds holding NRSN

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Geode Capital Management's NRSN Position: Q1 2026 in Review

Geode Capital Management held its NeuroSense Therapeutics (NRSN) position steady in Q1 2026 at 15,870 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #4483.

Geode Capital Management first reported a position in NRSN in Q4 2023 and has held it in 10 quarters since. The position peaked at $30K in Q2 2025. 13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

Geode Capital Management held 15,870 shares of NeuroSense Therapeutics worth $12K as of Q1 2026.
Geode Capital Management left its NeuroSense Therapeutics share count unchanged in Q1 2026.
NeuroSense Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4483 holding.
Geode Capital Management first reported a position in NeuroSense Therapeutics in Q4 2023 and has held it in 10 quarters since.
Geode Capital Management's NeuroSense Therapeutics position peaked at $30K in Q2 2025.
13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.